Silencing of MINOR in DCs improves short-term antitumor efficacy. Mice were injected with 5 × 10⁵ A20-HA cells 5 days before treatment with weekly DC vaccines, which were transduced with either LV-control-siRNA or LV-MINOR-siRNA and pulsed with MHC II–restricted HA peptide. HA-reactive T cells (6.5) were administered at the time of the first vaccine. Mice were followed for survival (killed as appropriate according to Institutional Animal Care and Use Committee guidelines). Shown is 1 of 3 similar experiments; tumor progression was significantly delayed in mice receiving the DC vaccine transduced with the MINOR-siRNA (t test conducted on results at day 38).